Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy.
OBJECTIVE
To report the long term effect of the combined treatment with high dose intravenous immunoglobulins (i.v.Ig) and oral cyclophosphamide (CTX) in patients with multifocal motor neuropathy, and to determine whether the association of oral CTX in these patients may help to delay and, possibly, suspend i.v.Ig infusions.


METHODS
Six patients with multifocal motor neuropathy responding to an initial course of i.v.Ig (0.4 g/kg/day for five consecutive days) were followed up for 37 to 61 (mean 47) months. All patients were subsequently treated with periodic i.v.Ig infusions (0.4 g/kg/day for two days at clinical worsening) and oral CTX (1-3 mg/kg/day). Improvement was assessed using the Rankin disability scale, a functional impairment scale for upper and lower limbs, and the MRC rating scale on the 20 most affected muscles. Electrophysiological and antiglycolipid antibody studies were performed before treatment, then yearly during follow up.


RESULTS
All patients improved during treatment and, by the end of follow up or before worsening after therapy suspension, the median Rankin (P=0.0335) and upper (P=0.0015) and lower limb (P=0.0301) impairment scores and the mean MRC (P=0.0561) score were improved. By that time the number of nerves with partial motor conduction block was reduced (P=0.0197) and antiglycolipid antibody titres had decreased in all but one patient. All patients required periodic i.v.Ig infusions to maintain improvement but, after three to seven months of oral CTX, the interval between i.v.Ig infusions could be progressively prolonged until, in three patients, both treatments could be stopped for up to two years before clinical worsening. The main complications, both related to oral CTX, were haemorrhagic cystitis in two patients and persistent amenorrhea in one patient.


CONCLUSIONS
I.v.Ig can induce and maintain improvement in multifocal motor neuropathy but does not eradicate the disease. Oral CTX may help to induce a sustained remission but it is not devoid of side effects and might therefore be reserved for patients with multifocal motor neuropathy who require frequent i.v.Ig infusions to maintain improvement.
Meucci
N
N
Institute of Clinical Neurology, Centro Dino Ferrari, University of Milan, IRCCS Ospedale Maggiore Policlinico, Italy.
Cappellari
A
A
Barbieri
S
S
Scarlato
G
G
Nobile-Orazio
E
E
D000284:Administration, Oral; D000328:Adult; D000477:Alkylating Agents / Q000627:therapeutic use*; D001132:Arm / Q000503:physiopathology; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007866:Leg / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D016472:Motor Neuron Disease / Q000188:drug therapy* / Q000503:physiopathology; D012720:Severity of Illness Index; D013997:Time Factors
D000477:Alkylating Agents; D016756:Immunoglobulins, Intravenous; D003520:Cyclophosphamide